[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"2502e95e-e4c1-4a43-8fda-b4937c0e5814","acronym":"","url":"https://clinicaltrials.gov/study/NCT03093428","created_at":"2021-01-29T07:14:23.379Z","updated_at":"2025-02-25T16:05:59.369Z","phase":"Phase 2","brief_title":"Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC","source_id_and_acronym":"NCT03093428","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 06/09/2017","start_date":" 06/09/2017","primary_txt":" Primary completion: 04/09/2020","primary_completion_date":" 04/09/2020","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-01-24"},{"id":"3d98dd1f-987f-4c68-94e3-38adc1f3cdfa","acronym":"BAT-RAD","url":"https://clinicaltrials.gov/study/NCT04704505","created_at":"2021-01-19T20:51:15.415Z","updated_at":"2025-02-25T17:24:58.474Z","phase":"Phase 2","brief_title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04704505 - BAT-RAD","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-18"},{"id":"c6eb5752-3b02-4b81-89d4-72c52d5a889a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04090398","created_at":"2021-01-18T20:01:06.898Z","updated_at":"2024-07-02T16:34:58.839Z","phase":"Phase 2","brief_title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","source_id_and_acronym":"NCT04090398","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"9b675762-36d2-4b01-a1bb-64cbf3e1132c","acronym":"COMRADE","url":"https://clinicaltrials.gov/study/NCT03317392","created_at":"2021-01-18T16:22:57.486Z","updated_at":"2024-07-02T16:35:02.836Z","phase":"Phase 1/2","brief_title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","source_id_and_acronym":"NCT03317392 - COMRADE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HRD • CD4","pipe":" | ","alterations":" HRD","tags":["HRD • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Suspended","enrollment":" Enrollment 133","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-17"},{"id":"843d1194-3194-45a2-a9e4-951c039304c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02258451","created_at":"2021-01-18T10:36:32.901Z","updated_at":"2025-02-25T17:07:40.914Z","phase":"Phase 2","brief_title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02258451","lead_sponsor":"Bayer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Completed","enrollment":" Enrollment 283","initiation":"Initiation: 06/04/2015","start_date":" 06/04/2015","primary_txt":" Primary completion: 01/22/2020","primary_completion_date":" 01/22/2020","study_txt":" Completion: 10/28/2022","study_completion_date":" 10/28/2022","last_update_posted":"2023-11-24"},{"id":"9192c317-9830-4f24-91e8-9c91a8ad0583","acronym":"","url":"https://clinicaltrials.gov/study/NCT02463799","created_at":"2021-01-18T11:49:25.358Z","updated_at":"2025-02-25T17:22:48.447Z","phase":"Phase 2","brief_title":"Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC","source_id_and_acronym":"NCT02463799","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IFNG • ICAM1","pipe":"","alterations":" ","tags":["IFNG • ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/22/2016","start_date":" 02/22/2016","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 12/12/2019","study_completion_date":" 12/12/2019","last_update_posted":"2021-07-08"},{"id":"098d33f4-6759-4d74-9fca-b364e3f3f2d4","acronym":"PRORADIUM","url":"https://clinicaltrials.gov/study/NCT02925702","created_at":"2021-10-27T06:44:55.098Z","updated_at":"2024-07-02T16:36:50.907Z","phase":"","brief_title":"PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.","source_id_and_acronym":"NCT02925702 - PRORADIUM","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" AR","pipe":" | ","alterations":" AR amplification • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride)"],"overall_status":"Unknown status","enrollment":" Enrollment 161","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2020-01-27"},{"id":"e8a0af9e-afc6-4742-823e-11da45748c35","acronym":"","url":"https://clinicaltrials.gov/study/NCT02204943","created_at":"2021-01-18T10:19:19.555Z","updated_at":"2025-02-25T17:22:25.811Z","phase":"Phase 1","brief_title":"Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02204943","lead_sponsor":"Duke University","biomarkers":" ALPL","pipe":"","alterations":" ","tags":["ALPL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/06/2015","start_date":" 05/06/2015","primary_txt":" Primary completion: 07/31/2017","primary_completion_date":" 07/31/2017","study_txt":" Completion: 07/31/2017","study_completion_date":" 07/31/2017","last_update_posted":"2018-06-08"},{"id":"de68fa81-0711-43fb-bd84-5d2a2aa266cd","acronym":"EIFFEL","url":"https://clinicaltrials.gov/study/NCT02880943","created_at":"2021-01-18T14:08:36.270Z","updated_at":"2024-07-02T16:37:27.707Z","phase":"Phase 1/2","brief_title":"Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)","source_id_and_acronym":"NCT02880943 - EIFFEL","lead_sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","biomarkers":" TNFRSF11B","pipe":"","alterations":" ","tags":["TNFRSF11B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride)"],"overall_status":"Unknown status","enrollment":" Enrollment 42","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2016-11-08"}]